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Tel-Aviv, IsraelAbstractCarriers of carbapenem-resistant Klebsiella pneumoniae (CRKP) are increasingly recognised through active surveillance in much of the world.
We studied incidence, aetiology and predictors of bloodstream infections (BSI) among such carriers. Via a retrospective cohort study
conducted in a tertiary care teaching hospital, we examined occurrence of BSI within 45 days of CRKP carrier detection. Three nested
case-control studies were conducted to analyse parameters associated with all-cause (ALL), Gram-negative rod (GNR) and CRKP BSI.
Cases and controls were compared with respect to demographics, clinical parameters and recent receipt of antibiotics. A total of 431
patients were identiﬁed as CRKP carriers (28% by clinical culture, 72% by rectal surveillance), mean age was 75.2 years. Twenty percent
of the patients (n = 85) developed BSI, of them 80% (n = 68) with GNR. Of 83 GNR isolates, 58 (70%) were Enterobacteriaceae, of
which 19 were CRKP and 20 were extended-spectrum β-lactamase (ESBL) producers (23% and 24% of total GNR, respectively); 29% of
the GNR isolates were nonfermenters (14.5% Pseudomonas aeruginosa, 14.5% Acinetobacter baumannii). Mechanical ventilation predicted
ALL BSI (p = 0.04), whereas Clostridium difﬁcile–associated diarrhoea predicted GNR BSI (p = 0.04). Receipt of broad-spectrum
antibiotics (piperacillin-tazobactam, amikacin, imipenem) was signiﬁcantly associated with ALL BSI or GNR BSI. No exposure
independently predicted CRKP BSI. We conclude that patients detected as CRKP carriers are at high risk for BSI within 45 days of
detection, primarily with multidrug-resistant GNR. Lack of predictive factors differentiating between pathogens and associated high
mortality raises once more the dilemma regarding the appropriate empiric therapy for CRKP carriers who develop severe sepsis.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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E-mail: sharona@tlvmc.gov.ilIntroductionCarbapenem-resistant Klebsiella pneumoniae (CRKP) has
emerged as a major public health threat, imposing considerable
clinical and epidemiological challenges. These strains are usually
extensively drug resistant, have very few available treatmentMicrobiol Infect 2015; 21: 30–34
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.08.001options, and those are often of uncertain effectiveness and
carry high toxicity [1-3]. Clinicians in various parts of the world
are increasingly encountering patients who carry or are infec-
ted by CRKP strains. In the United States, 543 of 4577 (12%)
Klebsiella spp. strains reported to the National Healthcare
Safety Network in 2009–2010 as associated with nosocomial
infections were resistant to carbapenems [4]. European au-
thorities report local outbreaks in numerous countries across
the continent, with a high proportion of CRKP in bloodstream
isolates in Greece, Italy, and Cyprus (proportion of resistance
68%, 27% and 15%, respectively [5,6]). Multiple countries in the
Middle East and southern Mediterranean basin, South America
and Asia are affected. CRKP has become endemic in the Indianious Diseases. Published by Elsevier Ltd. All rights reserved
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organisms, CRKP is usually acquired after prolonged hospital
stay and tends to affect debilitated patients with poor functional
status, who require intensive care and are heavily exposed to
antibiotics [8–10]. CRKP bloodstream infections (BSI) are
associated with an immense case fatality rate of 40% to 70%
[11–13]. This increased mortality rate is partly related to the
aforementioned host factors and partly to the infection with
these extensively drug-resistant strains for which targeted
treatment is almost always delayed, frequently of uncertain
effectiveness, and occasionally nonexistent.
The reservoir of patients carrying CRKP is increasing, and
these patients are more often recognised because recommen-
dations to control the spread of CRKP include active surveillance
of high-risk patients [14–18]. Thus, physicians are encountering
more often the clinical scenario of a recognisedCRKP carrierwho
develops signs of infection. Currently, little is known regarding
incidence, predictors and outcome of infections, BSI speciﬁcally,
among CRKP carriers. The clinician thus faces an intricate
decision-making processwhen empirically treating a patient with a
history of CRKP colonisation or infection, due to patient selection
(i.e. mostly elderly, often frail patients with several comorbidities),
infection-related morbidity and mortality and a limited antibiotic
arsenal. Data regarding infections among CRKP carriers are
therefore of paramount importance to assist decisionmaking. The
aim of this study was twofold: to assess the rates and characterise
all BSI, Gram-negative rod BSI (GNR BSI) and CRKP BSI among a
cohort of CRKP carriers; and to identify demographic and clinical
predictors of CRKP BSI within this group.MethodsStudy setting and patient population
The Tel-Aviv Medical Centre is a 1500-bed, tertiary-care
teaching hospital. An active surveillance policy for CRKP car-
riage among high-risk patients has been implemented in the
hospital since 2007. Those arriving from long-term care facil-
ities, another acute care facility or abroad are screened for
CRKP upon admission. Over 1000 patients are screened
monthly, and carriage rate is roughly 0.5% with a great majority
of the isolates belonging to the ST-258 subtype [18]. Electronic
databases were searched to identify all CRKP-positive patients,
whether discovered by active surveillance or a clinical culture
between January 2008 and April 2010. The study was approved
by the local ethics committee.
Study design
We conducted a series of retrospective, nested case-control
studies within a cohort of CRKP carriers, each followed upClinical Microbiology and Infection © 2014 European Society of Clinical Microbiolofor a period of 45 days since the ﬁrst isolation of CRKP. BSI was
deﬁned using CDC criteria (http://www.cdc.gov/nhsn/pdfs/
pscmanual/17pscnosinfdef_current.pdf). The case groups were
deﬁned as follows: 1) ALL BSI, which included all patients with
BSI within the CRKP cohort; 2) GNR BSI; 3) CRKP BSI. In each
of these case-control studies, the different-group CRKP car-
riers with BSI were compared with control CRKP-carrier
cohort patients. Study entry day was deﬁned as the ﬁrst
CRKP isolation date; exit day was deﬁned as BSI, death, or the
passage of 45 days since ﬁrst CRKP isolation. Because we aimed
at assessing BSI rate among known CRKP carriers, patients
from whom the ﬁrst isolation site of CRKP was the blood were
excluded, i.e. we excluded every patient with CRKP BSI within
2 days of study entry.
Data abstraction
Data were extracted from hospital electronic medical records
according to a preprepared questionnaire. Cases and controls
were compared regarding demographics (age and sex,
admission from home vs. an institution), functional status
(poor was deﬁned as a score of 14 or less in the Norton
pressure ulcers risk scale), comorbid conditions (diabetes
mellitus, cardiovascular disease, pulmonary disease, liver dis-
ease, malignancy), surgery and/or mechanical ventilation
before BSI, the presence of Clostridium difﬁcile, the source of
the CRKP-positive culture, recent receipt of antibiotics and
the classes of antibiotics received before a positive culture
was obtained (Table 1).
Statistical analysis
Statistical analysis was performed using SPSS version 18. We
used Cox regression for univariate survival analysis to compare
the different groups of bacteraemic patients within the CRKP-
carrier cohort. Covariates that were statistically signiﬁcant (p
<0.05) were selected for Cox regression multivariate model.
Comparison of exposure to antibiotics (deﬁned daily dose) by
days was performed using a time-dependent covariate (i.e.
accumulative exposure to antibiotics); p <0.05 was considered
to be statistically signiﬁcant.ResultsBetween January 2008 and April 2010, 431 patients were iden-
tiﬁed as carriers of CRKP either from clinical samples (28%, n =
121) or from a rectal swab as part of active surveillance (72%,
n = 310). As previously published [11–13], CRKP carriers often
were old, with poor functional status and comorbidities
(Table 1). Within 45 days of initial CRKP detection, 85 patients
(19.7%) developed BSI (ALL BSI group), of whom 68 (80%) hadgy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 30–34
TABLE 1. Clinical and demographic characteristics of CRKP-
carrier cohort vs. ALL BSI and GNR BSI groups
Entire cohort
n (%)
ALL BSI
n (%)
GNR BSI
n (%)
Number 431 85 68
Female sex 226 (52) 48 (56.5) (54.4)37
Mean age (y, SD) 75.2 (±17.2) 73.9 (±16.3) 75.3 (±17.4)
Resident of long-term care
facilities
157 (36.4) 29 (34.1) 22 (32.4)
Norton score (mean, SD) 11.3 (±4.2) 11.4 (±4.6) 11.4 (±4.7)
Diabetes 139 (32.3) 34 (40) 26 (38.2)
Cardiovascular disease 103 (23.9) 22 (26) 20 (29.4)
Respiratory disease 63 (14.6) 17 (20) 13 (19.1)
Malignancy 63 (14.6) 15 (17.6) 13 (19.1)
Any comorbidity 255 (59.2) 55 (64.7) 45 (66.2)
CRKP by screen 310 (72) 59 (69.4) 45 (65.2)
Surgery 47 (11) 10 (12) 10 (15)
Mechanical ventilation 44 (10.2) 10 (11.8)* 8 (11.8)
Clostridium difﬁcile–
associated diarrhoea
37 (8.6) 6 (7.1) 6 (8.8)*
Antibiotic exposure
Levoﬂoxacin 8 (1.9) 4 (4.7) 2 (2.9)
Ceftazidime 26 (6.0) 9 (10.6)* 4 (5.9)
Piperacillin-tazobactam 43 (10.0) 15 (17.6)* 13 (19.1)*
Amikacin 21 (4.9) 8 (9.4)* 6 (8.8)
Ertapenem 24 (5.6) 8 (9.4) 7 (10.3)
Imipenem 20 (4.6) 8 (9.4)* 7 (10.3)*
Meropenem 16 (3.7) 5 (5.9) 4 (5.9)
Colistin 62 (14.4) 19 (22.4)* 15 (22.1)*
CRKP, carbapenem-resistant Klebsiella pneumoniae; ALL, all patients; BSI, bloodstream
infections; GNR, Gram-negative rod.
*Signiﬁcant predictor vs. cohort in univariate analysis, p <0.05.
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CRKP BSI (22.4% of ALL BSI, 4.5% of the entire cohort). High
rates of extended-spectrum β-lactamase (ESBL) producers and
MDR nonfermenters were noted as well (Fig. 1); 66% of GNR
isolates were resistant to ceftazidime, 68% to ciproﬂoxacin, 53%
to gentamicin and 41% to piperacillin-tazobactam. To identify
predictors of BSI within the cohort of CRKP carriers, we
compared demographic and clinical characteristics of the various
BSI groups with those of the CRKP-positive cohort population
(Table 1). Surprisingly, the various BSI groups had very similar
characteristics to the general cohort and very few predictors
were found. Being mechanically ventilated predicted being in theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectALL BSI group (p = 0.04) and having Clostridium difﬁcile–
associated diarrhoea (CDAD) predicted belonging to the GNR
BSI group (p = 0.04). The CRKP BSI group showed a trend
toward having one or more comorbid conditions (p = 0.06), but
otherwise shared similar characteristics with the rest of the
cohort (not shown). We also examined previous exposure to
antibiotic agents among the groups; the use of several broad-
spectrum antibiotics (e.g. carbapenems, piperacillin-
tazobactam) was signiﬁcantly associated with having any BSI
(ALL BSI group), as well as GNR BSI. However, there was not a
single antibiotic to which exposure predicted CRKP BSI. In
multivariable analysis, carbapenems, amikacin and colistin pre-
dicted being in the ALL BSI group. Multivariable models for the
GNR BSI group identiﬁed CDAD and broad-spectrum antibi-
otics as predictors. A multivariable model for predictive factors
for CRKP bacteraemia could not be established. The 7-day case
fatality rate was 24.4% for patients with GNR BSI excluding
CRKP, and 38.9% for patients with CRKP bacteraemia
(p = 0.26).DiscussionThe emergence and spread of CRKP in many parts of the world,
and recommendations for enhanced control measures including
active screening of high risk populations [14–18], have resulted
in recognition of a growing number of hospitalised patients as
CRKP carriers. These patients are often old, with multiple
comorbid conditions, and are heavily exposed to antibiotics
[8–10]. When a CRKP carrier develops sepsis, the clinician
faces a difﬁcult decision regarding empiric therapy: which or-
ganisms should be covered? What is the expected resistance
pattern? Here, within a large cohort of patients with CRKP, we
attempted to deﬁne the occurrence of each group of pathogens
and to identify predictors that may assist the clinician inFIG. 1. Bloodstream infection (BSI)
rates and causative pathogens within
45 days of entering a carbapenem-
resistant Klebsiella pneumoniae
(CRKP) cohort. GNR, Gram-
negative rod; MRSA, methicillin-
resistant Staphylococcus aureus;
ESBL, extended-spectrum
β-lactamase.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 30–34
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identiﬁed as a CRKP carrier, nearly 20% of the patients devel-
oped BSI. The great majority (80%) of the BSI events in these
patients were caused by GNR, of which nearly a quarter were
caused by CRKP (n = 19, 4.5% of the entire cohort). Very few
predictors of BSI in general, and predictors of BSI involving
speciﬁc pathogens, were identiﬁed. Patients affected by any BSI
as well as patients affected speciﬁcally by GNR BSI were sicker,
as reﬂected by a higher proportion of mechanically ventilated
patients, greater exposure to antibiotics and a higher propor-
tion of patients with CDAD. Conversely, no speciﬁc predictor
for CRKP bacteraemia was identiﬁed and mortality, although
higher, did not signiﬁcantly differ between this group and the
GNR-excluding CRKP BSI group. This ﬁnding may be partly
related to insufﬁcient power of our study (the CRKP BSI group
included only 19 patients) and partly to the homogeneity of the
entire cohort, which included severely ill, aged patients [19,20].
Noteworthy, a similar study regarding Staphylococcus aureus BSI
showed a rate of 7.7% among nasal carriers of this bacterium
[21]. Similarly, there were very few demographic or clinical
predictors for developing BSI within the S. aureus carrier group.
Nevertheless, our ﬁnding of the high proportion of BSI caused
by CRKP and other multidrug-resistant causative pathogens
(including ESBL-producers, MDR Acinetobacter baumannii and
methicillin-resistant S. aureus), reﬁnes the clinical dilemma. The
currently available agents active against CRKP, namely, colistin,
tigecycline and aminoglycosides, may be toxic and are of
doubtful efﬁcacy in certain clinical conditions. Likewise, they are
believed to be less efﬁcacious than β-lactam agents to treat
other Gram-negative pathogens (which were more common
than CRKP). Moreover, upon increased use of colistin, resis-
tance among various Gram-negative bacteria should be antici-
pated and is of great concern, especially among carbapenem-
resistant strains [22,23]. Thus, although a prudent use of anti-
microbials is cardinal, especially in high-risk population, the
epidemiology of BSI within the CRKP cohort suggests that
combination chemotherapy may be advisable in cases of severe
sepsis [24–26]. In conclusion, although this is a single-centre
retrospective study, the data presented highlight the high like-
lihood of patients with CRKP to develop BSI, and the high
proportion in which CRKP is the causative pathogen. Our
ﬁndings illustrate the challenges in treating these patients and
call for larger, prospective studies assessing infection risks
among CRKP carriers and the efﬁcacy of therapeutic
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